News
Dr. Ronald Manning Joins SNBL USA to Enhance Acute Radiation Syndrome Program
SNBL USA, the experts in primate research, announced the appointment of Ronald Manning, PhD, as senior technical director for model development. Manning will be heading SNBL USA’s new Acute Radiation Syndrome (ARS) Program.
SNBL USA’s ARS program includes countermeasure evaluation resources, from efficacy demonstrations to nonclinical GLP studies under the FDA’s Animal Efficacy Rule in both rodent and nonhuman primate animal models. This new program allows SNBL USA to support drug development efforts for mitigating and treating radiation injury and removing radioactive materials from the body. In addition to managing the ARS program, Manning will also lead efforts to expand SNBL USA’s animal models into new countermeasure areas such as chemical and biologic threats and traumatic brain injury.
Prior to joining SNBL USA, Manning worked as chief of the Chemical, Radiological and Nuclear (CRN) Medical Countermeasures Branch within the Biomedical Advanced Research and Development Authority, working in the office of the assistant secretary for preparedness and response at the U.S. Department of Health and Human Services. His extensive background in medical countermeasures against CRN threats will assist SNBL USA’s initiatives aimed at national preparedness.
With more than 30 years in the industry, Manning has a depth of experience that includes work in project management, market research, standards development, operations, analytical methods development and recruitment. A graduate of the University of California with doctorate and bachelor’s degrees in chemistry, he has authored or co-authored more than 60 publications, including numerous publications on the management and assessment of radiological emergencies.
“We are excited to welcome someone as practiced and knowledgeable as Ron to our team,” said Dr. Thomas Beck, SNBL USA president and chief operating officer. “I am confident Ron’s leadership will accelerate and enrich our ARS Program. His unique combination of countermeasure assessment and project definition, and his substantial industry background, will provide an important new element as we expand services. SNBL USA has made a significant investment in this exciting area with the recent acquisition of our linear accelerator and associated bunker and infrastructure. Ron has the experience and knowledge to best leverage these assets to advance this important national security effort.”
For additional information regarding SNBL USA services and capabilities, contact SNBL USA at +1.425.322.1950 or info@snblusa.com.
About SNBL USA, Ltd.
Headquartered in Everett, Wash., SNBL USA, Ltd. offers a unique range of safety assessment services to fulfill its commitment to help free patients from suffering. Managed and operated by a team world renowned for its wide-ranging NHP experience and expertise, SNBL offers programs ranging from regulatory toxicology to customized study designs. SNBL’s specialized capabilities include safety assessment of biologics, reproductive toxicology, cardiovascular, respiratory and CNS pharmacology, immunotoxicology and carcinogenicity..
###